News Headlines Article

FDA approves first drug for form of thyroid cancer
Los Angeles Times

Federal regulators Wednesday approved the first drug treatment for a rare form of late-stage thyroid cancer.

Patients with metastatic medullary thyroid cancer who received the drug, vandetanib, went an additional six months without progression of disease compared to patients who received a sugar pill, according to a statement by the Food and Drug Administration.

It is too soon to tell whether the additional time without progression of the disease will translate into longer survival, the FDA said.